Retatrutide 40mg Vial

Retatrutide 40mg Vial is a research-grade lyophilized peptide formulation supplied in a sterile vial for laboratory and investigational use only. It contains Retatrutide, a triple receptor agonist that targets GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors, which are key pathways involved in metabolic regulation, appetite control, and energy balance.

Retatrutide is currently an investigational compound studied in clinical trials for obesity and metabolic disorders, where triple-receptor activation has been associated with significant effects on weight reduction, improved insulin sensitivity, and increased energy expenditure in controlled research settings. However, it is not approved for general medical use, prescription dispensing, or over-the-counter sale.

Each vial contains 40mg of Retatrutide in a freeze-dried (lyophilized) powder form, intended for controlled laboratory research. It must be reconstituted with a suitable sterile diluent before use in experimental protocols. Dosage, handling, and storage are strictly limited to research environments under appropriate regulatory compliance.